Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Tappenden, P. orcid.org/0000-0001-6612-2332, Simpson, E. orcid.org/0000-0001-7353-5979, Hamilton, J. et al. (5 more authors) (2018) Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. ISSN 1170-7690

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © Springer Nature Switzerland AG 2018. This is an author produced version of a paper subsequently published in PharmacoEconomics. Uploaded in accordance with the publisher's self-archiving policy. The final publication is available at Springer via https://doi.org/10.1007/s40273-018-0713-7.
Dates:
  • Accepted: 24 September 2018
  • Published: 24 September 2018
  • Published (online): 24 September 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
The University of Sheffield > Sheffield Teaching Hospitals
Funding Information:
FunderGrant number
NATIONAL INSTITUTE FOR HEALTH RESEARCH14/25/02
Depositing User: Symplectic Sheffield
Date Deposited: 31 Oct 2018 15:42
Last Modified: 31 Oct 2018 15:42
Published Version: https://doi.org/10.1007/s40273-018-0713-7
Status: Published online
Publisher: Springer
Refereed: Yes
Identification Number: https://doi.org/10.1007/s40273-018-0713-7

Download

Accepted Version


Embargoed until: 24 September 2019

Filename: IbrutinibForMCL_PE_final_revised_clean_WRversion .pdf

Request a copy

Share / Export

Statistics